menu
    • menu
    [{"orgOrder":0,"company":"George Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Telmisartan","moa":"||Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"George Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"George Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Inapplicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"George Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"George Medicines \/ Inapplicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"George Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"George Medicines \/ Inapplicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Telmisartan","moa":"||Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"George Medicines \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"George Medicines \/ Bausch Health"},{"orgOrder":0,"company":"George Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Telmisartan","moa":"||Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"George Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"George Medicines \/ Inapplicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Telmisartan","moa":"||Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"George Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"George Medicines \/ Inapplicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Telmisartan","moa":"||Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"George Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"George Medicines \/ Inapplicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Telmisartan","moa":"||Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"George Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"George Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Honeybrains Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Honeybrains Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Honeybrains Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Honeybrains Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorio Elea Phoenix","sponsor":"Carlos R. Rojo | University of Buenos Aires","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Laboratorio Elea Phoenix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorio Elea Phoenix \/ Carlos R. Rojo | University of Buenos Aires","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorio Elea Phoenix \/ Carlos R. Rojo | University of Buenos Aires"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Yuhan Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Inapplicable"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HK inno.N \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Boehringer Ingelheim brand of telmisartan

    Menu

    Boehringer Ingelheim brand of telmisartan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            George Medicines

                            United Kingdom arrow
                            Peptide Process CMC
                            Not Confirmed

                            George Medicines

                            United Kingdom arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            George Medicines Announces Approval of Widaplik, a New Single Pill Combination Treatment

                            Details : Widaplik (telmisartan, amlodipine and indapamide), a new single pill combination treatment which is approved for hypertension in adults, including initial treatment.

                            Product Name : Widaplik

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 09, 2025

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            George Medicines

                            United Kingdom arrow
                            Peptide Process CMC
                            Not Confirmed

                            George Medicines

                            United Kingdom arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Bausch Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            George Medicines, Bausch Health Sign Licensing Agreement for GMRx2 in Canada

                            Details : Under the terms of the licensing agreement, Bausch Health will hold the exclusive rights to commercialize, GMRx2 in Canada, Mexico etc. It is being evaluated for the treatment of hypertension.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 13, 2025

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Bausch Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Honeybrains Biotech

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed

                            Honeybrains Biotech

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of HB-1 for Panic Disorder

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 03, 2024

                            Lead Product(s) : Telmisartan

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            George Medicines

                            United Kingdom arrow
                            Peptide Process CMC
                            Not Confirmed

                            George Medicines

                            United Kingdom arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            George Medicines Files NDA with FDA for Triple Combination Therapy for Hypertension

                            Details : GMRx2 is a triple combination of telmisartan, amlodipine and indapamide, in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhage.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 08, 2024

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Chong Kun Dang Pharm

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed

                            Chong Kun Dang Pharm

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan

                            Therapeutic Area : Nephrology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Telmisartan Compared With Losartan

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 28, 2024

                            Lead Product(s) : Telmisartan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            George Medicines

                            United Kingdom arrow
                            Peptide Process CMC
                            Not Confirmed

                            George Medicines

                            United Kingdom arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            George Medicines Completes Recruitment of First Phase III Hypertension Trial Investigating Novel Single-pill T...

                            Details : GMRx2 is a single-pill, multi-mechanism, triple combination of telmisartan, amlodipine and indapamide, in novel and proprietary dosage strengths and is in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhag...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 07, 2023

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Yuhan Corporation

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed

                            Yuhan Corporation

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 18, 2023

                            Lead Product(s) : Telmisartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Chong Kun Dang Pharm

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed

                            Chong Kun Dang Pharm

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive P...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 06, 2023

                            Lead Product(s) : Telmisartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            George Medicines

                            United Kingdom arrow
                            Peptide Process CMC
                            Not Confirmed

                            George Medicines

                            United Kingdom arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            George Medicines Provides Single-pill Triple Combination Candidate for Hypertension to VERONICA-Nigeria trial

                            Details : GMRx2 is George Medicine’s most advanced candidate in late-stage development. A single-pill triple combination, it contains low doses of the commonly used hypertension medications telmisartan, amlodipine and indapamide.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 09, 2022

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            HK inno.N

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed

                            HK inno.N

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteer...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 10, 2021

                            Lead Product(s) : Telmisartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth